Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Glenmark Pharmaceuticals Limited
WARNING LETTER
•Glenmark Pharmaceuticals Limited•May 20, 2022

Glenmark Pharmaceuticals Limited – FDA Warning Letter, May 20, 2022

Record Details

The FDA inspected Glenmark Pharmaceuticals Limited in Goa, India, from May 12-20, 2022, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B). The firm's June 12, 2022, response to the Form FDA 483 was deemed inadequate. Key violations include the failure to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192), specifically regarding desmopressin acetate tablets, leading to a voluntary recall. The firm also failed to establish adequate written procedures for production and process control (21 CFR 211.100(a)), evidenced by inadequate process validation for (b)(4) gel (b)(4)% and subsequent viscosity-related rejections. Furthermore, the company failed to establish and follow required laboratory control mechanisms (21 CFR 211.160(a)), including issues with chromatographic peak integration, manual data modification without controls, and incorrect minimum area calculations. Finally, batch production and control records were incomplete (21 CFR 211.188), lacking batch-specific data for compression machine reject limits. The FDA requires a written response within 15 working days detailing corrective actions and prevention measures, emphasizing that these are not an all-inclusive list of violations.

Company
Glenmark Pharmaceuticals Limited
Inspection date
May 20, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 0ac1907c-5a77-4f23-8229-957f8b7079ca

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.100(a)21 CFR 211.160(a)21 CFR 211.18821 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Glenmark Pharmaceuticals Limited
  • 483 - 2022-06-22June 22, 2022
  • 483 - 2019-04-20April 20, 2019
  • WARNING_LETTER - 2019-04-20April 20, 2019
  • 483 - 2017-11-11November 11, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Glenmark Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.